VistaGen Therapeutics, Inc. Analyst EPS Estimates
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 0 | -$0.36 | -$0.36 | -$0.36 |
Q2 2024 | 0 | -$0.40 | -$0.40 | -$0.40 |
Q3 2024 | 3 | -$0.40 | -$0.38 | -$0.39 |
Q4 2024 | 0 | -$0.46 | -$0.46 | -$0.46 |
Q1 2025 | 2 | -$0.51 | -$0.51 | -$0.51 |
Q2 2025 | 2 | -$0.34 | -$0.34 | -$0.34 |
Q3 2025 | 2 | -$0.37 | -$0.37 | -$0.37 |
Q4 2025 | 2 | -$0.34 | -$0.34 | -$0.34 |
Q1 2026 | 0 | -$0.34 | -$0.34 | -$0.34 |
VistaGen Therapeutics, Inc. Earnings Date And Information
VistaGen Therapeutics, Inc. last posted its earnings results on Tuesday, August 13th, 2024. The company reported $-0.35 earnings per share for the quarter, topping analysts' consensus estimates of $-0.41 by $0.06. The company had revenue of 84,000 for the quarter and had revenue of 1.06 M for the year. VistaGen Therapeutics, Inc. has generated $-2 earnings per share over the last year ($-1.52 diluted earnings per share) and currently has a price-to-earnings ratio of -2.78. VistaGen Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 7th, 2024 based on prior year's report dates.
VistaGen Therapeutics, Inc. Earnings History by Quarter
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
08/13/2024 | Q1 2025 | -$0.41 | -$0.35 | 0.06 | $298,650 | $84,000 |
06/11/2024 | Q4 2024 | -$0.34 | -$0.35 | -0.01 | $197,300 | |
02/13/2024 | Q3 2024 | -$0.31 | -$0.22 | 0.09 | $411,400 | |
11/09/2023 | Q2 2024 | -$0.68 | -$0.66 | 0.02 | $184,600 | $277,700 |
08/10/2023 | Q1 2024 | -$0.94 | $184,600 | $177,600 | ||
06/28/2023 | Q4 2023 | -$1.71 | $175,600 | |||
02/07/2023 | Q3 2023 | -$1.80 | -$1.42 | 0.38 | $179,600 | |
11/10/2022 | Q2 2023 | -$2.40 | -$2.54 | -0.14 | $310,050 | $-892,500 |
08/11/2022 | Q1 2023 | -$2.70 | -$2.87 | -0.17 | $310,100 | |
06/23/2022 | Q4 2022 | -$1.80 | -$2.43 | -0.63 | $38,900 | |
02/10/2022 | Q3 2022 | -$2.40 | -$1.56 | 0.84 | $338,667 | $357,900 |
11/10/2021 | Q2 2022 | -$1.50 | -$1.99 | -0.49 | $351,367 | $358,000 |
08/12/2021 | Q1 2022 | -$1.50 | -$1.22 | 0.28 | $394,633 | $354,100 |
06/29/2021 | Q4 2021 | -$1.50 | -$1.29 | 0.21 | $441,900 | |
02/11/2021 | Q3 2021 | -$1.50 | -$1.96 | -0.46 | $334,000 | $313,600 |
11/12/2020 | Q2 2021 | $0.60 | -$1.47 | -2.07 | $2.50 M | $334,000 |
08/13/2020 | Q1 2021 | -$3.00 | -$1.83 | 1.17 | $0 | |
06/29/2020 | Q4 2020 | -$3.00 | -$2.08 | 0.92 | $0 | |
02/13/2020 | Q3 2020 | -$2.10 | -$4.14 | -2.04 | $0 | |
11/06/2019 | Q2 2020 | -$4.50 | -$3.76 | 0.74 | $0 |
VistaGen Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is VistaGen Therapeutics, Inc.'s earnings date?
VistaGen Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 7th, 2024 based off last year's report dates.
-
Did VistaGen Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, VistaGen Therapeutics, Inc. (:VTGN) reported $-0.35 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.41 by $0.06.
-
How can I listen to VistaGen Therapeutics, Inc.'s earnings conference call?
The conference call for VistaGen Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read VistaGen Therapeutics, Inc.'s conference call transcript?
The conference call transcript for VistaGen Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does VistaGen Therapeutics, Inc. generate each year?
VistaGen Therapeutics, Inc. (:VTGN) has a recorded annual revenue of $1.06 M.
-
How much profit does VistaGen Therapeutics, Inc. generate each year?
VistaGen Therapeutics, Inc. (:VTGN) has a recorded net income of $1.06 M. VistaGen Therapeutics, Inc. has generated $-1.52 earnings per share over the last four quarters.
-
What is VistaGen Therapeutics, Inc.'s price-to-earnings ratio?
VistaGen Therapeutics, Inc. (:VTGN) has a price-to-earnings ratio of -2.78 and price/earnings-to-growth ratio is -0.03.